Conference Track

Chronic Lymphocytic Leukemia

Source: CCO Independent Conference Coverage of the American Society of Hematology 2007 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Bendamustine Superior to Chlorambucil in Treatment-Naive CLL
CD69 Positivity Predicts Poor Survival in Patients With B-Cell Chronic Lymphocytic Leukemia
In Patients With CLL, Survival Poor When Cytopenia Is Due to Bone Marrow Failure
Phosphatase Inhibition Studies Reveal Dysregulation of Signaling in CLL Cells
Alemtuzumab Consolidation Therapy Associated With Severe Infections in Patients With CLL Who Achieve Complete Responses With Induction Therapy: Interim Safety Analysis of CALGB Study 10101
CFAR Highly Active in Patients With High-Risk CLL
First-Line Fludarabine vs Chlorambucil in Elderly Patients With CLL: Higher Response Rate but No Survival Advantage
Genomic Complexity Identifies Patients With Aggressive Chronic Lymphocytic Leukemia
CD38 Status Predicts Disease Progression for Patients With Monoclonal B-Cell Lymphocytosis
CLL Cell Count Independent Risk Factor for Progressive Lymphocytosis in Patients With Monoclonal B-Cell Lymphocytosis
High Rate of Serious Infections Following Alemtuzumab Consolidation Therapy in Patients With Chronic Lymphocytic Leukemia

Expert Analysis

Chronic Lymphocytic Leukemia

Program Director: Roy A. Beveridge, MD

Faculty:

John C. Byrd, MD
Michael J. Keating, MB BS
Kanti Rai, MD

Moderator: Robert S. Mocharnuk, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss new findings on potential genomic and phenotypic prognostic markers in chronic lymphocytic leukemia
Summarize newly reported trial data on first-line therapy of chronic lymphocytic leukemia
Discuss newly reported data on the infectious toxicity of alemtuzumab in consolidation therapy
Identify biomarkers reported to predict progression to clinical chronic lymphocytic leukemia in patients with monoclonal B-cell lymphocytosis

CME CREDIT INFORMATION

Release Date: 02/26/08

Expiration Date: 02/25/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.1 Nursing CE credits

Pharmacists: 1.1 contact hours (0.11 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.